6 March 2019 (Wednesday) - Oncologist Newsletter

The nice people at “The Oncologist” sent their update today. Several snippets including:

Most-Cited Articles in Hematology Oncology

Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma Douwe Postmus, Sarah Richard, Nathalie Bere et al. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma Yvette L. Kasamon, R. Angelo de Claro, Yaping Wang et al. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents Bruce D. Cheson, Sari Heitner Enschede, Elisa Cerri et al. The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project Daniel J. Sargent, Qian Shi, Christopher R. Flowers et al.

Most-Cited Articles in Medical Oncology

Effectiveness of Oncologist‐Referred Exercise and Healthy Eating Programming as a Part of Supportive Adjuvant Care for Early Breast Cancer Amy A. Kirkham, Cheri L. Van Patten, Karen A. Gelmon et al. Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program Oliver Sartor, Nicholas J. Vogelzang, Christopher Sweeney et al. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer Kristen K. Ciombor, Tanios Bekaii‐Saab Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma Silvia Stacchiotti, Olivier Mir, Axel Le Cesne et al.